Perspective

The three fastest-growing trends in healthcare


Healthcare providers around the world are seeking to change the way that care is delivered to patients, due to increased pressure on budgets and higher demand for services.

A small minority of patients (with chronic or long-term conditions) often account for a large percentage of overall spending. By treating these patients more effectively and taking advantage of new technologies, healthcare providers can make significant cost savings.

Below are three of the fastest-growing trends in healthcare which can provide opportunities.

1. Glucose monitors

Wearable glucose monitors are one of the fastest new growth segments in healthcare. I think it is a great example of how technology can enable better monitoring of diabetic care, which is key to prevent patient complications.

For people with type 2 diabetes, wearable continuous glucose monitors reduce the need for finger-prick blood tests. This makes it much easier for sufferers of the condition to manage their health. The device uses a tiny sensor under the skin of the arm which is connected to a small transmitter patch on the surface of the skin.

The sensor reads blood sugar levels from fluid just beneath the skin and transmits them to your display device, which can be a hand-held device (such as a smartphone) or in the case of a type 1 diabetic, an insulin pump (known as an integrated system).

For many people, the first time they may have been aware of the device was when former UK prime minister Theresa May revealed one at the top of her left arm after she was pictured wearing a sleeveless dress during a dinner with US President Donald Trump in July 2018.

2. Drug therapy

In the past few years there have been huge medical breakthroughs in cancer treatments, transforming the way the disease is treated and leading to significantly higher survival rates.

Immunotherapy drugs, which work to treat cancer by harnessing the patient’s immune system, are the first group of drugs to have a significant impact on survival rates. The survival rate in advanced melanoma, for example, is now 20% to 30%, whereas previously it was less than 5%, according to the results of medical trials conducted by Merck. Survival rates in early stage lung cancer have also improved, with around 60% of patients treated with these drugs still alive after 18 months, compared with around 40% of those treated with chemotherapy, the Merck trials found.

This step change in cancer therapy has led to rapid adoption globally. Indeed, many of the big global drug companies, such as Roche, AstraZeneca and Bristol Myers, have been investing heavily in these type of drugs, which are increasingly becoming the new backbone of cancer treatments. 

3. Gene therapy

Every year small numbers of children are born with gene mutations that tragically either lead to early death or developmental issues.  Pre-natal/new-born screening and gene sequencing has enabled the early detection of these mutations. 

The first gene therapy products have recently been approved that offer the potential of a one-time cure to correct or offset specific errant genes. 

In May, Zolgensma was approved to treat spinal muscular atrophy, a neuromuscular disorder that leads to the loss of motor neurons and progressive muscle wasting. Half of babies diagnosed with the condition at birth die within 12 months.

The promise of gene therapy has been discussed for the past three decades but is only now the technology exists to make this a reality and highlights some of the new opportunities available in healthcare.

 

The views and opinions contained herein are those of the Authors, and may not necessarily represent views expressed or reflected in other Schroders communications, strategies or funds.

 

This document is intended to be for information purposes only. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The material is not intended to provide, and should not be relied on for, accounting, legal or tax advice, or investment recommendations. Information herein is believed to be reliable but Schroders does not warrant its completeness or accuracy. No responsibility can be accepted for errors of fact or opinion. Reliance should not be placed on the views and information in the document when taking individual investment and/or strategic decisions.

 

Past performance is not a reliable indicator of future results, prices of shares and the income from them may fall as well as rise and investors may not get back the amount originally invested.

 

Schroders has expressed its own views in this document and these may change (to be used if the 1st statement above is not being used).

 

Schroders will be a data controller in respect of your personal data. For information on how Schroders might process your personal data, please view our Privacy Policy available at www.schroders.com/en/privacy-policy or on request should you not have access to this webpage.

 

Issued by Schroder Investment Management (Europe) S.A., 5, rue Höhenhof, L-1736 Senningerberg, Luxembourg. Registered No. B 37.799. For your security, communications may be taped or monitored

 

The forecasts stated in the document are the result of statistical modelling, based on a number of assumptions. Forecasts are subject to a high level of uncertainty regarding future economic and market factors that may affect actual future performance. The forecasts are provided to you for information purposes as at today’s date. Our assumptions may change materially with changes in underlying assumptions that may occur, among other things, as economic and market conditions change. We assume no obligation to provide you with updates or changes to this data as assumptions, economic and market conditions, models or other matters change.